April 27, 2017 / 1:39 PM / 3 months ago

BRIEF-Roche's O'Day says has seen no more thromboembolic events with ACE910

1 Min Read

April 27 (Reuters) - Roche

* Drugs head Dan O'Day says access limitations for multiple sclerosis medicine Ocrevus in United States 'are really none'

* Says he is hopeful ACE910 will be available to hemophilia patients by end of 2017, early 2018

* O'Day says has seen no more significant thromboembolic events with ACE910 beyond those already reported

* Says Lucentis sales seen rising in FY2017, though pace may slow from 9 percent in first quarter Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below